Trials / Completed
CompletedNCT01942369
A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 402 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe changes in the intensity of specific endometriosis symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline (Triptorelin Acetate) treatment for up to 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triptorelin Acetate 3.75mg intramuscular injection | Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa). Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks. |
Timeline
- Start date
- 2013-09-16
- Primary completion
- 2018-07-13
- Completion
- 2018-07-13
- First posted
- 2013-09-16
- Last updated
- 2018-12-06
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01942369. Inclusion in this directory is not an endorsement.